A. Ribas

777 total citations
41 papers, 598 citations indexed

About

A. Ribas is a scholar working on Oncology, Molecular Biology and Organic Chemistry. According to data from OpenAlex, A. Ribas has authored 41 papers receiving a total of 598 indexed citations (citations by other indexed papers that have themselves been cited), including 29 papers in Oncology, 18 papers in Molecular Biology and 8 papers in Organic Chemistry. Recurrent topics in A. Ribas's work include Melanoma and MAPK Pathways (17 papers), Cancer Immunotherapy and Biomarkers (16 papers) and CAR-T cell therapy research (13 papers). A. Ribas is often cited by papers focused on Melanoma and MAPK Pathways (17 papers), Cancer Immunotherapy and Biomarkers (16 papers) and CAR-T cell therapy research (13 papers). A. Ribas collaborates with scholars based in United States, Australia and Spain. A. Ribas's co-authors include Richard Kefford, Jesús Gómez-Navarro, Axel Hauschild, Claus Garbe, C.J.A. Punt, Dmitri Pavlov, J.B.A.G. Haanen, Igor Puzanov, Grant A. McArthur and J. A. Sosman and has published in prestigious journals such as Journal of Clinical Oncology, Blood and Cancer.

In The Last Decade

A. Ribas

41 papers receiving 583 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name h Career Trend Papers Cites
A. Ribas United States 14 478 286 191 48 45 41 598
Virginia Picasso Italy 12 400 0.8× 314 1.1× 197 1.0× 101 2.1× 56 1.2× 16 661
Megan Duggan United States 14 326 0.7× 222 0.8× 361 1.9× 52 1.1× 55 1.2× 25 631
Christine Longvert France 12 353 0.7× 233 0.8× 106 0.6× 59 1.2× 40 0.9× 34 525
Viviana Bozón United States 11 525 1.1× 195 0.7× 377 2.0× 58 1.2× 30 0.7× 28 662
Marcello Curvietto Italy 10 434 0.9× 180 0.6× 239 1.3× 108 2.3× 26 0.6× 29 618
Darab Kamanabrou Germany 6 372 0.8× 305 1.1× 139 0.7× 81 1.7× 24 0.5× 7 517
Brian Belmontes United States 13 421 0.9× 322 1.1× 169 0.9× 203 4.2× 84 1.9× 22 757
Mark Voskoboynik Australia 15 504 1.1× 181 0.6× 233 1.2× 165 3.4× 53 1.2× 76 678
MacLean Hall United States 9 637 1.3× 307 1.1× 399 2.1× 67 1.4× 38 0.8× 21 811
R. Gonzalez Chile 10 260 0.5× 271 0.9× 76 0.4× 53 1.1× 28 0.6× 43 459

Countries citing papers authored by A. Ribas

Since Specialization
Citations

This map shows the geographic impact of A. Ribas's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by A. Ribas with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites A. Ribas more than expected).

Fields of papers citing papers by A. Ribas

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by A. Ribas. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by A. Ribas. The network helps show where A. Ribas may publish in the future.

Co-authorship network of co-authors of A. Ribas

This figure shows the co-authorship network connecting the top 25 collaborators of A. Ribas. A scholar is included among the top collaborators of A. Ribas based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with A. Ribas. A. Ribas is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
2.
Robert, Caroline, Dirk Schadendorf, Georgina V. Long, et al.. (2021). 1084P PLATForM: Descriptive analysis from a randomised, phase II study of novel spartalizumab combinations in previously treated unresectable/metastatic melanoma. Annals of Oncology. 32. S898–S898. 4 indexed citations
3.
Long, Georgina V., Mohammed Milhem, A. Amin, et al.. (2018). Phase Ib/II, open label, multicenter, study of the combination of SD-101 and pembrolizumab in patients with advanced melanoma who are naïve to anti-PD-1 therapy. Annals of Oncology. 29. viii736–viii736. 4 indexed citations
4.
Hauschild, Axel, Paul B. Chapman, Caroline Robert, et al.. (2016). Impact of key prognostic factors on long-term overall survival in BRAFV600-mutated metastatic melanoma patients treated with vemurafenib in the BRIM-3 study. Melanoma Research. 2 indexed citations
5.
6.
Ma, Jun, Jean‐Jacques Grob, James Larkin, et al.. (2016). Estimating the percentage of patients with advanced melanoma achieving long-term survival with pembrolizumab (Pembro) treatment in KEYNOTE-006. Annals of Oncology. 27. vi382–vi382. 1 indexed citations
7.
Long, Georgina V., Atkinson, F. Stephen Hodi, et al.. (2016). Pembrolizumab plus ipilimumab for advanced melanoma : results of the keynote-029 expansion cohort. 12. 60–61. 7 indexed citations
8.
Lewis, Karl D., A. Ribas, R. Gonzalez, et al.. (2015). 3340 Treatment beyond progression in advanced BRAF-mutated melanoma with vemurafenib and cobimetinib: Results from the BRIM7 trial. European Journal of Cancer. 51. S679–S679. 2 indexed citations
9.
10.
Yan, Y., Grant A. McArthur, Thomas F. Gajewski, et al.. (2014). Vemurafenib and Cobimetinib Potently Inhibit Ps6 Signaling in Brafv600 Mutation–Positive Locally Advanced or Metastatic Melanoma from Brim7 Study. Annals of Oncology. 25. iv378–iv378. 2 indexed citations
11.
Chapman, Paul B., Axel Hauschild, Caroline Robert, et al.. (2011). Phase III randomized, open-label, multicenter trial (BRIM3) comparing BRAF inhibitor RG7204 with dacarbazine in patients with V600E BRAF-mutated melanomas.. Journal of Clinical Oncology. 29(15_suppl). LBA4–LBA4. 2 indexed citations
12.
Ribas, A., Lynn M. Schuchter, R. Gonzalez, et al.. (2011). BRIM-2: An open-label, multicenter phase II study of vemurafenib in previously treated patients with BRAF V600E mutation-positive metastatic melanoma.. Journal of Clinical Oncology. 29(15_suppl). 8509–8509. 107 indexed citations
13.
Bulanhagui, C. A., Jesús Gómez-Navarro, Scott Antonia, et al.. (2008). Prognostic role of prior cytokine immunotherapy in outcome of treatment with tremelimumab (CP-675,206) in patients with metastatic melanoma. Journal of Clinical Oncology. 26(15_suppl). 3057–3057. 3 indexed citations
14.
Bellmunt, J, et al.. (2002). Feasibility Trial of Methotrexate–Paclitaxel as a Second Line Therapy in Advanced Urothelial Cancer. Cancer Investigation. 20(5-6). 673–685. 27 indexed citations
15.
Bellmunt, J, et al.. (1997). Feasibility trial of high-dose 7-day continuous-infusion ifosfamide given on an outpatient basis. Cancer Chemotherapy and Pharmacology. 40(3). 273–276. 6 indexed citations
16.
Ribas, A., et al.. (1997). Life-threatening toxicity of oral tegafur-uracil (UFT) plus leucovorin. Clinical Oncology. 9(4). 269–270. 1 indexed citations
17.
Albanell, Joan, J Bellmunt, Raquel Molina, et al.. (1996). Node-negative breast cancers with p53(-)/HER2-neu(-) status may identify women with very good prognosis.. PubMed. 16(2). 1027–32. 40 indexed citations
18.
19.
Aurer, Igor, A. Ribas, & Gale Rp. (1990). What is the role of recombinant colony stimulating factors in bone marrow transplantation?. PubMed. 6(2). 79–87. 20 indexed citations
20.
Brugarolas, Antonio, et al.. (1979). Iron toxicity studies of quelamycin.. PubMed. 63(5). 909–13. 3 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Virginia Picasso Breakdown of academic impact, for papers by Megan Duggan Breakdown of academic impact, for papers by Christine Longvert Breakdown of academic impact, for papers by Viviana Bozón Breakdown of academic impact, for papers by Marcello Curvietto Breakdown of academic impact, for papers by Darab Kamanabrou Breakdown of academic impact, for papers by Brian Belmontes Breakdown of academic impact, for papers by Mark Voskoboynik Breakdown of academic impact, for papers by MacLean Hall Breakdown of academic impact, for papers by R. Gonzalez
Rankless by CCL
2026